{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:00:34Z","timestamp":1791896434566,"version":"4.3.4"},"reference-count":30,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2003,10,1]]},"abstract":"<jats:p> Purpose: T-cell acute lymphoblastic leukemia (T-ALL) accounts for 10% to 15% of newly diagnosed cases of childhood acute lymphoblastic leukemia (ALL). Historically, T-ALL patients have had a worse prognosis than other ALL patients. <\/jats:p><jats:p> Patients and Methods: We reviewed the outcomes of 125 patients with T-ALL treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium trials between 1981 and 1995. Therapy included four- or five-agent remission induction; consolidation therapy with doxorubicin, vincristine, corticosteroid, mercaptopurine, and weekly high-dose asparaginase; and cranial radiation. T-ALL patients were treated the same as high-risk B-progenitor ALL patients. Fifteen patients with T-cell lymphoblastic lymphoma were also treated with the same high-risk regimen between 1981 and 2000. <\/jats:p><jats:p> Results: The 5-year event-free survival (EFS) rate for T-ALL patients was 75% \u00b1 4%. Fourteen of 15 patients with T-cell lymphoblastic lymphoma were long-term survivors. There was no significant difference in EFS comparing patients with T-ALL and B-progenitor ALL (P = .56), although T-ALL patients had significantly higher rates of induction failure (P &lt; .0001), and central nervous system (CNS) relapse (P = .02). The median time to relapse in T-ALL patients was 1.2 years versus 2.5 years in B-progenitor ALL patients (P = .001). There were no pretreatment characteristics associated with worse prognosis in patients with T-ALL. <\/jats:p><jats:p> Conclusion: T-ALL patients fared as well as B-progenitor patients on DFCI ALL Consortium protocols. Patients with T-ALL remain at increased risk for induction failure, early relapse, and isolated CNS relapse. Future studies should focus on the identification of and treatment for T-ALL patients at high risk for treatment failure. <\/jats:p>","DOI":"10.1200\/jco.2003.10.116","type":"journal-article","created":{"date-parts":[[2003,9,25]],"date-time":"2003-09-25T23:21:48Z","timestamp":1064532108000},"page":"3616-3622","source":"Crossref","is-referenced-by-count":289,"title":["Childhood T-Cell Acute Lymphoblastic Leukemia: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Experience"],"prefix":"10.1200","volume":"21","author":[{"given":"John M.","family":"Goldberg","sequence":"first","affiliation":[{"name":"From the Department of Pediatric Oncology and the Department of Biostatistical Science, Dana-Farber Cancer Institute; the Division of Hematology\/Oncology, Children\u2019s Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA; the Department of Pediatrics, Stanford University School of Medicine, Stanford, CA; the Department of Pediatrics, Division of Hematology\/Oncology, University of Rochester Medical Center, Rochester, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis B.","family":"Silverman","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology and the Department of Biostatistical Science, Dana-Farber Cancer Institute; the Division of Hematology\/Oncology, Children\u2019s Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA; the Department of Pediatrics, Stanford University School of Medicine, Stanford, CA; the Department of Pediatrics, Division of Hematology\/Oncology, University of Rochester Medical Center, Rochester, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna E.","family":"Levy","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology and the Department of Biostatistical Science, Dana-Farber Cancer Institute; the Division of Hematology\/Oncology, Children\u2019s Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA; the Department of Pediatrics, Stanford University School of Medicine, Stanford, CA; the Department of Pediatrics, Division of Hematology\/Oncology, University of Rochester Medical Center, Rochester, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia Kimball","family":"Dalton","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology and the Department of Biostatistical Science, Dana-Farber Cancer Institute; the Division of Hematology\/Oncology, Children\u2019s Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA; the Department of Pediatrics, Stanford University School of Medicine, Stanford, CA; the Department of Pediatrics, Division of Hematology\/Oncology, University of Rochester Medical Center, Rochester, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Gelber","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology and the Department of Biostatistical Science, Dana-Farber Cancer Institute; the Division of Hematology\/Oncology, Children\u2019s Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA; the Department of Pediatrics, Stanford University School of Medicine, Stanford, CA; the Department of Pediatrics, Division of Hematology\/Oncology, University of Rochester Medical Center, Rochester, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Lehmann","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology and the Department of Biostatistical Science, Dana-Farber Cancer Institute; the Division of Hematology\/Oncology, Children\u2019s Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA; the Department of Pediatrics, Stanford University School of Medicine, Stanford, CA; the Department of Pediatrics, Division of Hematology\/Oncology, University of Rochester Medical Center, Rochester, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey J.","family":"Cohen","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology and the Department of Biostatistical Science, Dana-Farber Cancer Institute; the Division of Hematology\/Oncology, Children\u2019s Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA; the Department of Pediatrics, Stanford University School of Medicine, Stanford, CA; the Department of Pediatrics, Division of Hematology\/Oncology, University of Rochester Medical Center, Rochester, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Sallan","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology and the Department of Biostatistical Science, Dana-Farber Cancer Institute; the Division of Hematology\/Oncology, Children\u2019s Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA; the Department of Pediatrics, Stanford University School of Medicine, Stanford, CA; the Department of Pediatrics, Division of Hematology\/Oncology, University of Rochester Medical Center, Rochester, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara L.","family":"Asselin","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology and the Department of Biostatistical Science, Dana-Farber Cancer Institute; the Division of Hematology\/Oncology, Children\u2019s Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA; the Department of Pediatrics, Stanford University School of Medicine, Stanford, CA; the Department of Pediatrics, Division of Hematology\/Oncology, University of Rochester Medical Center, Rochester, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197504172921604"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Sallan SE: T-cell acute lymphoblastic leukemia in children. Hamatol Bluttransfus 26:121,1981\u2013123,","DOI":"10.1007\/978-3-642-67984-1_18"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1211"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198609113151101"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.10.2514.2514"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.4.740"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.1.237"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1395::AID-CNCR25>3.0.CO;2-2"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401980"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R11","unstructured":"Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163,1966\u2013170,"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401973"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401965"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401962"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401978"},{"key":"R16","unstructured":"Reiter A, Schrappe M, Riehm H, et al: Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM group report. Blood 95:416,2000\u2013421,"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401310"},{"key":"R18","unstructured":"Asselin BL, Shuster JJ, Amylon M, et al: Improved event-free survival (EFS) with high dose methotrexate (HDM) in T-cell lymphoblastic leukemia and advanced lymphoblastic lymphoma (T-NHL): A Pediatric Oncology Group (POG) Study. Proc Am Soc Clin Oncol 20:367,2001,  (abstr 1464)"},{"key":"R19","unstructured":"Pieters R, Kaspers G, Veerman A, et al: Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia 7:392,1993\u2013397,"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401129"},{"key":"R21","unstructured":"Schrappe M, Reiter A, Riehm H, et al: Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. Blood 95:3310,2000\u20133322,"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.2.564.564"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(93)90516-X"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.8.2786"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401693"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.2.411"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198907203210302"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2848"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390904"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3221"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2003.10.116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:27:09Z","timestamp":1653510429000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2003.10.116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,1]]},"references-count":30,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2003,10,1]]}},"alternative-id":["10.1200\/JCO.2003.10.116"],"URL":"https:\/\/doi.org\/10.1200\/jco.2003.10.116","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10,1]]}}}